ArticleCell death discovery2026
ATP6V1B2 alleviates hepatic steatosis by promoting lysosomal acidification in hepatocytes.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common metabolic disorder characterized by the abnormal accumulation of fat in the liver. ATP6V1B2, an essential subunit of the vacuolar ATPase (V-ATPase) complex, plays a pivotal role in its function and assembly. Despite its importance, the regulatory role of ATP6V1B2 and its molecular mechanism in MASLD progression remain poorly understood. In this study, we observed a significant reduction in ATP6V1B2 expression in the serum of MASLD patients. Experimental results demonstrated that inhibiting ATP6V1B2 expression in liver cells led to increased lipid accumulation, aggravated oxidative stress, upregulation of fatty acid synthase (FASN), and impaired autophagic activity. Further investigation revealed that ATP6V1B2 promotes the lysosomal degradation of FASN by maintaining the acidic environment of lysosomes, thereby playing a crucial role in lipid metabolism regulation. These findings uncover the critical mechanism by which ATP6V1B2 contributes to MASLD development and suggest that restoring its function could offer novel therapeutic strategies for treating this condition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.